Fennec Pharmaceuticals Inc FENC:NASDAQ

Set AlertOptionsStreaming Charts
Last Price$5.71NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$5.66 (1)
Ask (Size)$5.76 (12)
Day Low / HighN/A - N/A
Volume35.7 K
Sell
Buy
Chart Style Historical Chart Icon Download historical data
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 07/01/2022

Timeframe
 

Fennec Pharmaceuticals Inc ( NASDAQ )

Price: $5.71
Change: +0.13 (2.33%)
Volume: 35.7 K
4:00PM ET 7/01/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Ovid Therapeutics Inc ( NASDAQ )

Price: $2.19
Change: +0.04 (1.86%)
Volume: 195.0 K
4:00PM ET 7/01/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Assertio Holdings Inc ( NASDAQ )

Price: $3.15
Change: +0.20 (6.78%)
Volume: 1.9 M
4:00PM ET 7/01/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Spectrum Pharmaceuticals Inc ( NASDAQ )

Price: $0.77
Change: -0.01 (1.33%)
Volume: 1.7 M
4:00PM ET 7/01/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Sesen Bio Inc ( NASDAQ )

Price: $0.80
Change: -0.01 (1.42%)
Volume: 4.3 M
4:00PM ET 7/01/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain

Read more news Recent News

--Wedbush Lifts Price Target for Fennec Pharmaceuticals to $11 From $10, Maintains Outperform Rating
1:55PM ET 5/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Fennec Pharmaceuticals Q1 Net Loss Narrows
6:12AM ET 5/12/2022 MT Newswires

Fennec Pharmaceuticals (FENC) reported a Q1 net loss Thursday of $0.14 per diluted share, narrowing from a $0.18 loss a year earlier. Two analysts polled...

Fennec Pharmaceuticals Resubmits New Drug Application for Pedmark
6:24AM ET 3/24/2022 MT Newswires

Fennec Pharmaceuticals (FENC) said Thursday it has resubmitted its new drug application for Pedmark to the US Food and Drug Administration. Pedmark is a...

--Wedbush Lifts Price Target for Fennec Pharmaceuticals to $10 From $9, Maintains Outperform Rating
2:02PM ET 2/28/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow
10:59AM ET 6/04/2022 Seeking Alpha

Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow
2:44PM ET 3/31/2022 Seeking Alpha

Wall Street Breakfast: What Moved Markets
8:03AM ET 12/04/2021 Seeking Alpha

Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?
7:16PM ET 10/29/2021 Seeking Alpha

Company Profile

Business DescriptionFennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC. View company web site for more details
AddressResearch Triangle Park
Durham, North Carolina 27709
Phone+1.919.636.4530
Number of Employees3
Recent SEC Filing06/16/20224
Chief Executive Officer & DirectorRostislav C. Raykov
Chief Financial OfficerRobert C. Andrade
ControllerMark Gowland

Company Highlights

Price Open$5.67
Previous Close$5.58
52 Week Range$3.82 - 10.08
Market Capitalization$148.8 M
Shares Outstanding26.1 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.62
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-93.74%

Analyst Ratings as of 05/31/2022

Buy
3
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset